ArticleClinical research in cardiology : official journal of the German Cardiac Society2019
Patient preference for therapies in hypertension: a cross-sectional survey of German patients.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guidelines for the appropriate use of renal denervation systems in Japan: endorsed by the Japanese Society of Hypertension (JSH), the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS), and their positioning in the JSH 2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Guideline
- The role of renal denervation for the treatment of hypertension in patients with chronic kidney disease: a position paper of the Italian Society of Nephrology.Journal of nephrology · 2025Guideline
- Applying persuasive messages to reduce public outdoor smoking: A pseudo-randomized controlled trial.Applied psychology. Health and well-being · 2023Trial
- Cost-Effectiveness and Budget Impact Analysis of Radiofrequency Renal Denervation for Uncontrolled and Resistant Hypertension in Italy.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia.BMC cardiovascular disorders · 2026Article
- The Role of Renal Denervation in the Treatment of Hypertension in Canada: A Case-Based Discussion from the Canadian Hypertension Specialists Society.American journal of hypertension · 2026Review
- Patient Selection and Renal Denervation.Current hypertension reports · 2026Review
- Self-care Practices of Hypertensive Adult Female Patients in the City of Marikina amidst the COVID-19 Lockdown: A Phenomenological Inquiry.Acta medica Philippina · 2026Article
- Renal Denervation in Asia: 2025 Asia Renal Denervation Consortium (ARDeC) Consensus Statement Endorsed by the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network.Hypertension (Dallas, Tex. : 1979) · 2026Review
- A Blueprint for Building a Renal Denervation Program.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Review
- Renal denervation for hypertension.Nature reviews. Cardiology · 2025Review
- Evaluating Veterans' Preferences for Renal Denervation for Treatment of Difficult-to-Control Hypertension: A Single-Center Survey Study.Health science reports · 2025Article
- Impact of expected blood pressure reduction on patient preferences for pharmaceutical and renal denervation treatment.Journal of hypertension · 2025Article
- Medication Changes After Renal Denervation: Current Evidence and Patient Perspectives.Journal of the American Heart Association · 2024Review
- Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?).Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Cardiovascular intervention and therapeutics · 2024Article
- Reimagining Medication Adherence: A Novel Holistic Model for Hypertension Therapy.Patient preference and adherence · 2024Article
- 2023 update and perspectives.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Renal Denervation as a Complementary Treatment Option for Uncontrolled Arterial Hypertension: A Situation Assessment.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypertension is poorly controlled in numerous patients despite effective medication being available. Catheter-based renal denervation (RDN) has emerged as an alternative treatment option. We aimed to assess how likely patients with elevated blood pressure (BP) are to accept RDN as treatment option.
methodsA questionnaire-based cross-sectional survey was performed in patients with elevated BP in Germany. Data on patient demographics, clinical characteristics and treatment preferences were collected, anonymized and analyzed.
resultsOne thousand and eleven patients completed the survey. Mean age was 66 years (55% male). If not already on medication (n = 172), 38.2% of patients would prefer RDN. Of those already on drug therapy (n = 839), 28.2% would opt for RDN. Patients who were pro-RDN were younger (p < 0.0001) and more often male (p < 0.0001). Nineteen percent would choose RDN if it lowered systolic BP by at least 20 mmHg, more than 40% if they did not have to take any more pills thereafter, and 30% if it would lower BP by at least 10 mmHg. Experiences of side effects and drug adherence were identified as determinants of patient preference. Physicians were the main source of information regarding medical problems (95.5%) and influence patients' decision regarding therapies (98%).
conclusionsThis survey found that a significant proportion of patients would choose catheter-based RDN over lifelong pharmacotherapy. These patients were younger and more likely to be male but their expectation of the extent of BP decrease with RDN was high. Physicians are key mediators for treatment selection. They need to incorporate patient preferences into shared decision making.
Indexed as
Identifiers
30941492What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.